Celgene has also filed for approval of the R² regimen for these indolent forms of NHL in Europe and Japan, with an EMA verdict possible before the end of the year. Image Phil Taylor ...
Celgene's European leader Tuomo Pätsi talks to pharmaphorum about the firm's remarkable growth, which is set to continue thanks to myeloma blockbuster Revlimid and new psoriasis and psoriatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback